Triomics received $22 million to bring oncology AI to cancer centers

Triomics, a startup building an AI-powered platform to help oncologists and administrative staff automate data-heavy tasks like clinical trial matching and appointment setting, has raised $22 million in Series B funding.

The round was led by Battery Ventures, with participation from returning backers Nexus Venture Partners, Lightspeed, Y Combinator and others.

The good news is that breakthroughs in oncology are keeping patients alive longer. However, a welcome trend is the creation of dense, multi-year medical records, which take healthcare personnel a long time to review and decipher.

A typical medical chart includes the doctor’s progress notes, imaging and pathology reports, and even fax scans. “We have seen the medical records [with] “Thousands of pages of information,” Triomics co-founder Sarim Khan (pictured left) told TechCrunch.

Founded in 2021, the startup raised $15 million in a Series A in mid-2024. Triomics initially focused on helping doctors identify the most appropriate clinical trials for their patients, then expanded its platform as LLM capabilities grew. Over the past two years, Triomics has added verifiable patient summaries to its platform, showing key information directly within the tools doctors already use, without requiring them to switch apps.

By reducing appointment preparation time, these summaries give oncologists more time with their patients. Gaining efficiency has importance beyond individual appointments: in oncology, where patient histories are unusually complex and where staff burnout is a persistent problem, tools that reduce administrative burden have a major impact.

Triomics is also being used to automate the tedious task of submitting tumor reports to government registries, which is legal for cancer centers.

While AGI customers excel at basic abstracts, prominent institutions like Memorial Sloan Kettering (MSK) and the Yale Cancer Center use Triomics because its models are trained specifically on tumor data, Khan explained.

Most of Triomics’ direct competition comes from AI medical scribes like Abridge and Microsoft’s Nuance — tools that use AI to listen to and document conversations between patient and doctor — when it comes to summarizing patient charts.

Despite fierce competition, Triomics is growing rapidly. According to Khan, the startup has expanded its enterprise customer base fourfold over the past year, resulting in a 10x increase in annual recurring revenue.